Coya Therapeutics, Inc.

New research suggests a blood test can help identify and diagnose #neurodegenerative diseases like FTD, ALS, and PSP. More studies are needed but this could be incredibly important for diagnosing these conditions early for those who suffer from them. Coya is working on combination biologics to help treat neurodegenerative diseases like these. Be sure to speak with your doctor if you're experiencing any symptoms of these conditions. https://lnkd.in/gainX4T6 #Research #Biomarker #EndALS #EndFTD

Metabolic disorders occur when reactions in your body disrupt the normal process of breaking down food into fuel. When that happens, bodies can have too much of one substance or too little of another and that can throw off the body's ecosystem and make a person unhealthy. Obesity, Diabetes, and IBD are common metabolic disorders. Coya is working each day to enhance the function of Tregs to treat metabolic diseases like these. Learn more from MedlinePlus: https://lnkd.in/eQkWBjsx #Metabolic #Research #CoyaTherapeutics #Tregs

Coya's Howard Berman, PhD is one of InnovationMap's 3 Houston Innovators to know this week! We have filed intellectual property protection for a combination of COYA 301 and GLP-1, which could be a game-changer in the fight against Alzheimer’s disease. Howard said, “We believe that combination immunotherapy approaches will evolve to play a meaningful role in treating complex immune-based diseases that are driven by a host of pathophysiologic mechanisms.” Read more: https://lnkd.in/e2GV-ubn

Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer - https://lnkd.in/gNMtGURS Follow #citybiz on LinkedIn - https://lnkd.in/eBgXKiz8 Arun Swaminathan, Coya Therapeutics, Inc. #biotechnology #chiefexecutiveofficer

Today is #WorldSeniorCitizensDay! Seniors are more susceptible to neurodegenerative diseases like Alzheimer's and Dementia. Be sure to see your primary care provider annually and talk to your doctor if you're suffering from any of the signs of neurodegenerative decline like memory loss or balance problems. https://lnkd.in/emmiqMVU #CoyaTherapeutics #Seniors #Doctors #Prevention

In case you missed it, Coya Therapeutics announced yesterday Arun Swaminathan will succeed founder Dr. Howard Berman as CEO effective November 1st. Howard will transition into the role of Executive Chair of the Board. Current CEO Howard Berman, PhD said "Coya has grown quickly to a clinical stage company and is poised, in partnership with Dr. Reddy’s Laboratories, to potentially bring these therapies to patients who desperately need them. We believe Arun has an incredible skillset to execute on each of these milestones. He has been a foundational member of this team, instrumental in consummating our up to $700 million licensing transaction with Dr. Reddy’s Laboratories. At this stage of our evolution, I can think of no one better skilled and dedicated to take us to the next level, to progress our assets forward in the clinic and execute new business deals, all of which we believe will create value for our shareholders.” Read more about the change from Biz Journals: https://lnkd.in/gGrjNaGX #CoyaTherapeutics #Leadership #CEO

Earlier this month, Coya announced the filing of a patent for a combination of COYA 301 (a low-dose IL2) and GLP-1 that could be a game-changer in the fight against Alzheimer's disease. Learn all about it in this article from InnovationMap: https://lnkd.in/e9FuE3Qw #CoyaTherapeutics #Patent #EndALZ

NEWS: Coya Therapeutics promotes Arun Swaminathan Ph.D. to Chief Executive Officer effective November 1st, 2024. Dr. Howard Berman, the founder of Coya, will transition to Executive Chair of the Board. Learn more in our latest press release: https://lnkd.in/easQHMzK

Your immune system is there to protect the body from invading microorganisms. When your body triggers that response and attacks the very cells they are meant to protect, that can lead to a variety of autoimmune diseases. Coya is working on enhancing the function of Tregs to help treat autoimmune diseases like Addison disease and Celiac disease. Learn more from our partners at the Autoimmune Association: https://lnkd.in/eap4sSgi #CoyaTherapeutics #AutoImmune #Research #Therapies

Coya Therapeutics is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells, also called Tregs. Coya's combination biologics have already shown strong proof of concept data in ALS and Alzheimer's. Coya's lead candidate Coya 302 is the combination of low dose IL-2 and CTLA4-lg, synergistically enhancing Treg function and depletion of effector T cells and macrophages to further decrease inflammation, that can actually halt disease progression. Learn more about Coya's investigational therapies at coyatherapeutics.com. #CoyaTherapeutics #Tregs #Inflammation #Research #Development